- Conditions
- Tinnitus, Subjective, Tinnitus
- Interventions
- Nortriptyline + Topiramate, Verapamil + Paroxetine, Placebo
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 25 Years to 85 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Orange, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Interventions
- Valbenazine Oral Capsule
- Drug
- Lead sponsor
- Stephen Ruedrich
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Tinnitus
- Interventions
- Nortriptyline, Topiramate, Paroxetine, Verapamil
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 25 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
- Interventions
- Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 20
- States / cities
- La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more